Raymond James Financial Services Advisors Inc. raised its position in BioNTech SE (NASDAQ:BNTX – Get Rating) by 12.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,938 shares of the company’s stock after buying an additional 1,660 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in BioNTech were worth $2,244,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. US Bancorp DE raised its position in BioNTech by 8.2% in the first quarter. US Bancorp DE now owns 4,386 shares of the company’s stock valued at $749,000 after purchasing an additional 332 shares during the period. BlackRock Inc. increased its holdings in shares of BioNTech by 25.9% in the first quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after purchasing an additional 331,101 shares during the period. Great West Life Assurance Co. Can increased its stake in BioNTech by 522.3% in the 1st quarter. Great West Life Assurance Co. Can now owns 2,041 shares of the company’s stock valued at $371,000 after buying an additional 1,713 shares during the period. Cibc World Market Inc. increased its stake in BioNTech by 6.4% in the 1st quarter. Cibc World Market Inc. now owns 2,983 shares of the company’s stock valued at $509,000 after buying an additional 180 shares during the period. Finally, Sei Investments Co. grew its stake in shares of BioNTech by 58.1% during the 1st quarter. Sei Investments Co. now owns 145,886 shares of the company’s stock worth $24,882,000 after purchasing an additional 53,595 shares during the period. 15.29% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have weighed in on BNTX. HC Wainwright lowered their target price on BioNTech from $210.00 to $198.00 in a report on Tuesday. The Goldman Sachs Group set a $140.00 target price on BioNTech and gave the company a “neutral” rating in a research note on Tuesday, March 28th. Canaccord Genuity Group increased their target price on BioNTech from $191.00 to $203.00 and gave the company a “buy” rating in a research note on Tuesday, March 28th. Deutsche Bank Aktiengesellschaft lowered their price objective on BioNTech from $135.00 to $120.00 in a research note on Thursday, May 18th. Finally, Berenberg Bank set a $260.00 target price on BioNTech in a report on Tuesday, March 28th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $172.20.
BioNTech Stock Up 8.2 %
BioNTech (NASDAQ:BNTX – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $1.87. BioNTech had a net margin of 51.03% and a return on equity of 32.52%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the business posted $15.98 earnings per share. The company’s quarterly revenue was down 80.0% compared to the same quarter last year. On average, research analysts forecast that BioNTech SE will post 5.32 EPS for the current year.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.